Multiple myeloma is a type of cancer found in the blood’s plasma. Plasma cell dycrasias are other disorders and pre-cancers involving the same cell that causes multiple myeloma. All these blood disorders are treated at the University of Michigan Comprehensive Cancer Center’s Multidisciplinary Multiple Myeloma and Plasma Cell Dyscrasias Clinic. The clinic provides the finest in patient care through education, patient empowerment, clinical trial opportunities and participation with cancer specialists from other disciplines. Our team of blood cancer experts has sub-specialty training so we can offer patients with multiple myeloma and other plasma disorders the highest standard of care and access to the latest therapies and drugs.But multiple myeloma is unusual. The standard of care is changing rapidly because of abundant research projects and clinical trials that are extending life expectancy and quality of life. As a result, there are as many as 30 different options for treating the disease. In order to ensure the best treatment throughout Michigan, our specialists organized the Great Lakes Multiple Myeloma Working Group, an informal network with experts at other Michigan centers treating multiple myeloma. The shared goal is to find and bring the latest treatments and therapies to multiple myeloma patients not just at the University of Michigan, but throughout the state.
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT).
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
This randomized phase II trial studies how well ixazomib citrate and dexamethasone or ixazomib citrate, dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in treating patients with multiple myeloma that has returned after a period of improvement or does not respond to treatment.
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms.
This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment.
This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.
This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone.
This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies.
This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.
This phase I/II trial studies the side effects and best dose of idasanutlin and ixazomib citrate when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement.
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
1500 East Medical Center Drive
Ann Arbor, MI 48109
Create your account today and get matched to myeloma treatment centers and specialists around the US.
Weekdays 9am - 5pm EST